Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Family experiences of receiving treatment recommendations in a precision medicine trial for poor-prognosis childhood cancer.

NPJ genomic medicine·2026

Same author

Precision-guided therapy in H3K27-altered diffuse midline glioma.

Nature communications·2026

Same author

A single logic model capturing clinical, service, and implementation interventions using a practical example in pediatric precision medicine.

JBI evidence implementation·2026

Same author

A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma.

Neuro-oncology advances·2026

Same author

Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.

Molecular cancer therapeutics·2026

Same author

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Nature medicine·2026

Search research articles

Related Experiment Video

Updated: Apr 30, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Antibody therapy for pediatric leukemia.

Aditi Vedi¹, David S Ziegler¹

¹Kids Cancer Centre, Sydney Children's Hospital , Randwick, NSW , Australia ; School of Women and Children's Health, University of New South Wales , Randwick, NSW , Australia.

Frontiers in Oncology

|May 6, 2014

Summary

Novel antibody therapies, including monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific T cell engagers (BiTEs), show promise for treating relapsed pediatric leukemia, aiming to improve outcomes and reduce side effects.

Keywords:

acute lymphoblastic leukemia acute myeloid leukemia antibodies bispecific antibodies childhood leukemia conjugated antibodies monoclonal

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Apr 30, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Oncology
Immunotherapy
Pediatric Hematology

Background:

Relapsed pediatric leukemia has a poor prognosis despite advances in treatment.
Current treatments can lead to significant morbidity and mortality.
There is a need for novel, targeted therapies to improve survival rates.

Purpose of the Study:

To review recent advancements in targeted antibody-based therapies for pediatric leukemia.
To discuss the potential of monoclonal antibodies, ADCs, and BiTEs in treating childhood leukemia.
To highlight new treatment paradigms for relapsed disease.

Main Methods:

Review of current literature on antibody therapies in pediatric leukemia.
Analysis of ongoing clinical trials for monoclonal antibodies, ADCs, and BiTEs.
Synthesis of data on efficacy and safety profiles of novel agents.

Main Results:

Monoclonal antibodies are active in pediatric acute lymphoblastic leukemia (ALL) and in Phase III trials.
Antibody-drug conjugates (ADCs) are being tested in clinical trials for pediatric acute myeloid leukemia and ALL.
Bispecific T cell engager (BiTE) antibodies demonstrate significant promise for childhood leukemia.

Conclusions:

Antibody-based therapies offer a new paradigm for treating pediatric leukemia.
ADCs and BiTEs represent next-generation treatments with targeted efficacy.
These novel agents hold potential to improve outcomes for patients with relapsed leukemia.